IBX Shares Imagion Biosystems Limited
ASX · ASXLast in our picks 2026-10-13 — not in the current list; analysis below is from that screen
Molecular-imaging technology offers substantial milestone-driven upside, offset by clinical and funding risk.
Signal breakdown
- ▸Clinical development milestones are the principal near-term catalyst.
- ▾Below 50-day MA (-23.25%)
- ▸Volume 1.72× average — accumulation
- ▾Near 52-week low (3.3% of range)
Is IBX a buy right now?
Trend: IBX is trading below the 50-day average (-50.00%), RSI 45 — neutral momentum, with a 3-month return of -58.33%.
Valuation & quality: fundamentals show net margin 0.0%, revenue growth 1943.7% year on year.
Our screen: ACCUMULATE (score 1) — Molecular-imaging technology offers substantial milestone-driven upside, offset by clinical and funding risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | -50.00% | +100.00% | -50.00% | +0.00% | +0.00% | +0.00% | -100.00% |
Fundamentals
Technical signals
About Imagion Biosystems Limited
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses.
Sector: Healthcare · Industry: Diagnostics & Research · Australia · Website
Related Technology picks
Browse: all ASX stocks · Technology picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.